drugset / Trial / NCT00462696

MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer

NCT00462696

Completed 16 enrolled Institut Bergonié
NaSingle-groupOpen-labelDiagnostic

Summary

RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan better treatment. Drugs used in chemotherapy, such as epirubicin and docetaxel, may stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying MRI in evaluating early response to chemotherapy in women receiving chemotherapy for infiltrating breast cancer.

Timeline

Start
2006-02
Primary completion
2008-12-31
Completion
2008-12-31

Drugs

EvaluationDrugModalityDoseRoute
Background Docetaxel Small molecule 75 mg/m2
Background Epirubicin Small molecule 75 mg/m2